A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to Crizotinib

... Herein we report a novel ALK fusion partner, the Linc00308/D21S2088E intergenic region, that conferred responsiveness to crizotinib in a patient with lung adenocarcinoma (LUAD)... Thus, we have provided proof that patients with advanced NSCLC harboring a Linc00308/D21S2088E intergenic region ALK may benefit from crizotinib, expanding the spectrum of ALK fusion variants to optimize treated strategy. READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2020.03.009

Authors: Jian Zhang, Chang Zou, Chenzhi Zhou, Yifeng Luo, Qiong He, Yu Sun, Jianwen Zhou, Zunfu Ke

Case StudyKirk SmithJune 1, 2020Linc00308/D21S2088E, Intergenic Region, ALK Fusion, Crizotinib

A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma

Herein, we report a novel intergenic region between centromere protein A gene (CENPA) and dihydropyridiminase like 5 (DPYSL5)-ALK fusion in a patient with lung adenocarcinoma... To our knowledge, the shortcoming of traditional FISH and IHC was that the precise ALK fusion variants could not be identified, and the application of next-generation sequencing might be used as an optional and supplementary method. Because this patient received a remarkable tumor response after crizotinib therapy, our case report has expanded the spectrum of ALK fusion and provided useful information for precise ALK inhibitor administration in the future. READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.04.012

Authors: Xiaodong Fei, Liqun Zhu, Hongxuan Zhou, Chuang Qi, Chun Wang

EditorialKirk SmithSeptember 1, 2019Intergenic Region, CENPA, DPYSL5-ALK, Exon 20 Fusion Variant, Crizotinib, Lung Adenocarcinoma